# Michael Szarek

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michael-szarek/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,903 |
| Field | Lipoproteins and Cardiovascular Health |
| h-index | 55 |
| i10-index | 119 |
| Last Known Institution | St. Michael's Hospital |
| OpenAlex ID | https://openalex.org/A5072470914 |
| ORCID iD | https://orcid.org/0000-0002-0046-0264 |
| Works | 282 |

## Researcher papers

- [Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome](https://scholariq.org/papers/alirocumab-and-cardiovascular-outcomes-after-acute-coronary-syndrome/)
- [Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure](https://scholariq.org/papers/sotagliflozin-in-patients-with-diabetes-and-recent-worsening-heart-failure/)
- [Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease](https://scholariq.org/papers/sotagliflozin-in-patients-with-diabetes-and-chronic-kidney-disease/)
- [Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial](https://scholariq.org/papers/effect-of-alirocumab-a-monoclonal-antibody-to-pcsk9-on-long-term-cardiovascular/)
- [Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study](https://scholariq.org/papers/hemorrhagic-stroke-in-the-stroke-prevention-by-aggressive-reduction-in/)
- [Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial](https://scholariq.org/papers/effects-of-alirocumab-on-cardiovascular-and-metabolic-outcomes-after-acute/)
- [Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials](https://scholariq.org/papers/efficacy-and-safety-of-sglt2-inhibitors-with-and-without-glucagon-like-peptide-1/)

## Researcher topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Antiplatelet Therapy and Cardiovascular Diseases](https://scholariq.org/topics/antiplatelet-therapy-and-cardiovascular-diseases/)
- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

## Researcher university

- [St. Michael's Hospital](https://scholariq.org/institutions/st-michael-s-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.